四联疗法治疗幽门螺旋杆菌感染的临床体会

Quadruple therapy for Helicobacter pylori infection in clinical experience

目的观察以PPl为基础联合三种抗生素的四联疗法治疗幽门螺杆菌感染的根治效果及安全性。方法治疗组给埃索美拉唑20mg,阿莫西林1g,克拉霉素250mg及左氧氟沙星200mg,每日2次服药,对照组给埃索美拉唑20mg,阿莫西林lg,克拉霉素250mg,每日2次服药。疗程均为1周,治疗期间停用其他药物,疗程结束4周后复诊,观察Hp根除率、症状缓解率及不良反应发生率。结果疗程结束4周后复查Hp根除率治疗组为95.2%,对照组为76.7%,两组比较差异有统计学意义(P<0.05);治疗组症状缓解率83.3%,不良反应发生率14.6%,对照组症状缓解率82.6%,不良反应发生率16.7%,无统计学意义(P>0.05)。结论四联疗法可获得较高Hp根治率,疗程短,不良反应少,值得推广临床治疗。

Objective To observe the PPl-based combination of the three antibiotics, quadruple thera- py for cure of Helicobacter pylori infection efficacy and safety. Methods The treatment group to Esomeprazole 20mg, Amoxicillin lg, Clarithromycin 250mg and Levofloxacin 200mg, 2 times a day medication, the control group to Esomeprazole 20mg, Amoxicillin lg, Clarithromycin 250mg 2 times a day medication. Course of treat- ment were 1 week, disable other drugs during treatment. The end of treatment 4 weeks after the referral to ob- serve the Hp eradication rate, remission rate and the incidence of adverse reactions. Results After 4 weeks of the end of treatment review Hp eradication rate in the treated group was 95.2% , 76. 7% in the control group, the difference was statistically significant （ P 〈 0. 05 ） ; treatment group remission rate of 83.3%. Adverse reaction rate of 14. 6 % remission rate in the control group 82. 6%. The incidence of adverse reactions was 16. 7% , no statistical significance （ P 〉 0. 05 ）. Conclusion Hp quadruple therapy available to a higher cure rate, short duration and few adverse reaction, it is worth to promote clinical.